{"id":"W2912820618","doi":"10.1200/jco.2019.37.4_suppl.tps176","title":"A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Capecitabine; Tolerability; Peptide vaccine; Immunogenicity; Oncology; Internal medicine; HER2/neu; Cancer; Trastuzumab; Phases of clinical research; Chemotherapy; Monoclonal antibody; Breast cancer; Antibody; Epitope; Cancer research; Immunology; Adverse effect; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001641786,0.002354022,0.003340825,0.0007446297,0.0007221296,0.001275659,0.001646518,0.002084834,0.00511569],"category_scores_gemma":[0.0008717082,0.001050249,0.001634783,0.0006361303,0.002122875,0.00178013,0.0005025918,0.004324663,0.001303632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001374681,"about_ca_system_score_gemma":0.002753816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001639439,"about_ca_topic_score_gemma":0.002878979,"domain_scores_codex":[0.9993467,0.0002528437,0.00002934925,0.0001303093,0.00005661907,0.0001843187],"domain_scores_gemma":[0.9992342,0.00009136525,0.0001017855,0.00008631434,0.00005181022,0.0004345735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5512259,0.322019,0.002682032,0.001308629,0.0009557944,0.0005242694,0.0005145416,0.003072056,0.06401526,0.0004692037,0.002808749,0.05040454],"study_design_scores_gemma":[0.2982171,0.695004,0.001870562,0.00001767091,0.0001544596,0.0001374034,0.00004900962,0.000503069,0.002427328,0.0001177737,0.001481485,0.00002012809],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845969,0.001434697,0.0009670467,0.0005344363,0.0003442928,0.009149923,0.0009957241,0.0001022513,0.001874858],"genre_scores_gemma":[0.9744638,0.002645927,0.003526535,0.001279551,0.0004297358,0.01065391,0.002225713,0.000049103,0.004725875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00511569,"threshold_uncertainty_score":0.01711369,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1038290998928956,"score_gpt":0.4626013978379261,"score_spread":0.3587722979450305,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}